DMAC Competitors & Alternatives

Compare DiaMedica Therapeutics Inc with similar stocks in the same industry

Biotechnology

DMAC

Main Stock
$8.42
-4.27%
Tradestie Score
48
Market Cap
$354.59M
Analyst Upside
+84.2%

Supply-Chain & Ecosystem Map (Customers, Suppliers & Direct Competitors)

Bottleneck Score: 2/10 Drug Discovery Biotech Drug Design
Competitive Moat: None
Core Technology Stack: recombinant KLK1 protein, tissue kallikrein pathway modulation
Major Customers 3
future patients specialty clinics hospitals
Critical Suppliers 2
contract research organizations biomanufacturing partners
Direct Ecosystem Rivals 3

Top Competitors

221 stocks in Biotechnology
Company Price Market Cap P/E Score Action
VSTM Verastem, Inc.
$7.88
-3.67%
$541.60M - 54 Compare
CRVS Corvus Pharmaceuticals, Inc.
$10.55
-0.85%
$540.97M - 34 Compare
ZVRA Zevra Therapeutics, Inc. Common Stock
$9.31
+2.53%
$529.35M 9.7 56 Compare
LXRX Lexicon Pharmaceuticals, Inc.
$1.75
-2.51%
$512.39M - 37 Compare
RIGL Rigel Pharmaceuticals Inc. (New)
$43.73
-1.64%
$505.12M 2.8 54 Compare
RGNX REGENXBIO Inc.
$7.47
-2.23%
$493.52M - 44 Compare
INBX Inhibrx Biosciences, Inc. Common Stock
$77.32
-7.18%
$492.21M - 49 Compare
XOMA XOMA Royalty Corporation Common Stock
$40.17
-9.16%
$474.20M 28.2 46 Compare
ABSI Absci Corporation Common Stock
$7.73
-8.58%
$468.01M - 44 Compare
GLUE Monte Rosa Therapeutics, Inc. Common Stock
$9.11
-2.77%
$463.20M - 44 Compare

Data updated: Nov 16, 2026 | Industry: Biotechnology (SIC 2834)

221 stocks in this industry